サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1787225

神経痛治療の世界市場

Neuralgia Treatment

出版日
ページ情報
英文 276 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
神経痛治療の世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 276 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

神経痛治療の世界市場は2030年までに32億米ドルに達する

2024年に23億米ドルと推定される神経痛治療の世界市場は、2024年から2030年にかけてCAGR 6.0％で成長し、2030年には32億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである手術ベースの治療は、CAGR 6.8%を記録し、分析期間終了までに23億米ドルに達すると予測されます。薬剤ベースの治療分野の成長率は、分析期間中CAGR 3.8%と推定されます。

米国市場は6億1,850万米ドルと推定、中国はCAGR9.6％で成長予測

米国の神経痛治療市場は、2024年に6億1,850万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに6億6,010万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.9%と5.9%と予測されています。欧州では、ドイツがCAGR 3.9%で成長すると予測されています。

世界の神経痛治療市場- 主要動向と促進要因のまとめ

神経痛治療が疼痛管理で注目される理由とは？

神経痛は、激しく鋭く、しばしば慢性的な神経痛を特徴とする疾患で、患者のQOLを衰弱させることから、疼痛管理における主要な焦点となっています。神経痛は、神経の損傷、感染、炎症、あるいは糖尿病、多発性硬化症、帯状疱疹後合併症などの基礎疾患から生じることがあります。神経痛の一般的なタイプには、三叉神経痛、後頭神経痛、帯状疱疹後神経痛などがあり、それぞれに合った治療アプローチが必要です。非ステロイド性抗炎症薬（NSAIDs）やオピオイドなどの伝統的な鎮痛方法では、鎮痛効果が限定的であることが多く、抗けいれん薬、抗うつ薬、神経ブロック、神経調節療法など、より効果的な治療法に対する需要が高まっています。現在、神経痛治療の進歩には、微小血管減圧術（MVD）やラジオ波焼灼術（RFA）などの低侵襲外科的介入や、脊髄刺激（SCS）や標的ドラッグデリバリーシステムなどの新たな技術が含まれます。慢性疼痛疾患の有病率が世界的に上昇する中、神経痛治療市場では、長期的な緩和と患者の予後改善をもたらす革新的な疼痛管理ソリューションへの投資が増加しています。

効果的な神経痛治療を妨げる課題とは？

疼痛管理の進歩にもかかわらず、いくつかの課題が神経痛の効果的な治療の妨げとなっています。主な懸念事項のひとつは、神経痛の症状が他の神経障害性疼痛疾患と重複することがあるため、正確に診断することが難しく、誤診や治療の遅れにつながることです。また、神経痛は複雑であるため、治療効果が患者によって大きく異なり、試行錯誤を必要とし、苦痛を長引かせることもあります。さらに、オピオイドなど従来の神経痛治療の多くには、依存、中毒、副作用のリスクがあり、より安全な代替薬の開発が必要です。また、神経調節装置や外科的介入を含む高度な治療法には高額な費用がかかるため、特に発展途上地域では利用しにくくなっています。もう一つの大きな課題は、疼痛管理に対する認識や専門的な疼痛管理センターが不足していることで、多くの患者にとって過小診断や不十分な治療につながっています。さらに、新規の疼痛管理薬や器具に対する規制のハードルが市場参入を遅らせ、革新的な神経痛治療へのアクセスを制限しています。このような課題に対処するためには、調査への投資拡大、ヘルスケアプロバイダーに対する医療トレーニングの強化、そしてエビデンスに基づいた安価な疼痛管理療法へのアクセス改善が必要です。

イノベーションはどのように神経痛治療を変革しているのか？

神経痛治療市場は、疼痛緩和の改善、副作用の軽減、患者の転帰の改善を目的とした画期的な技術革新を目の当たりにしています。最も有望な進歩の一つは、経皮的電気神経刺激（TENS）、脊髄刺激（SCS）、後根神経節（DRG）刺激などの神経調節療法の使用であり、これらは神経レベルで痛みの信号を調節し、長期的な緩和をもたらします。もうひとつの大きな開発は、疼痛治療薬を患部の神経部位に直接放出し、全身的な副作用を軽減する標的ドラッグデリバリーシステムの出現です。遺伝子治療と再生医療もまた、幹細胞治療と神経成長因子が損傷した神経を修復し、正常な機能を回復する可能性を探る調査によって、注目を集めています。さらに、ラジオ波焼灼術（RFA）や凍結神経融解術の進歩により、大がかりな手術を必要とせずに痛みの経路を破壊することで、長期にわたる疼痛緩和を可能にする低侵襲な選択肢が提供されつつあります。人工知能（AI）と機械学習も疼痛管理に組み込まれつつあり、医師が患者固有の疼痛パターンと反応データに基づいて治療計画を個別化するのに役立っています。こうした技術革新が進化を続ける中、情勢はより効果的で侵襲性が低く、患者中心のソリューションへとシフトしており、永続的な痛みの緩和と生活の質の向上を実現しています。

神経痛治療市場の成長の原動力は？

神経痛治療市場の成長は、神経障害性疼痛疾患の有病率の上昇、慢性疼痛管理に対する意識の高まり、疼痛緩和技術の進歩など、いくつかの要因によって牽引されています。世界人口の高齢化は、帯状疱疹、糖尿病関連の神経損傷、退行性神経疾患などの症状を引き起こしやすく、神経痛の発生率上昇に寄与しています。さらに、非オピオイド系疼痛管理ソリューションが重視されるようになり、神経調節、標的ドラッグデリバリー、再生医療などの代替療法への需要が高まっています。疼痛管理クリニックや専門ヘルスケア施設の開発も、特に先進地域において、高度な神経痛治療へのアクセスを向上させています。さらに、研究開発への投資の増加により、生物製剤やAI支援治療計画などの新規治療法の導入が加速しています。慢性疼痛管理を促進する政府の取り組みや、革新的な治療を支援する償還政策が、市場の成長をさらに後押ししています。神経痛が公衆衛生上の重大な関心事であり続ける中、高度で効果的かつ利用しやすい治療オプションへの需要が高まり、疼痛管理の未来が形成され、世界中の何百万人もの罹患者の生活が改善されると予想されます。

セグメント

治療タイプ（手術ベース治療、薬物ベース治療）、エンドユーザー（病院・診療所エンドユーザー、外来手術センターエンドユーザー、その他エンドユーザー）

調査対象企業の例

  • Abbott Laboratories
  • Allergan plc
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc（GSK）
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32322

Global Neuralgia Treatment Market to Reach US$3.2 Billion by 2030

The global market for Neuralgia Treatment estimated at US$2.3 Billion in the year 2024, is expected to reach US$3.2 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Surgery-based Treatment, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Drug-based Treatment segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$618.5 Million While China is Forecast to Grow at 9.6% CAGR

The Neuralgia Treatment market in the U.S. is estimated at US$618.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$660.1 Million by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Neuralgia Treatment Market - Key Trends & Drivers Summarized

Why Is Neuralgia Treatment Becoming a Key Focus in Pain Management?

Neuralgia, a condition characterized by severe, sharp, and often chronic nerve pain, has become a major area of focus in pain management due to its debilitating impact on patients' quality of life. Neuralgia can result from nerve damage, infections, inflammation, or underlying conditions such as diabetes, multiple sclerosis, and postherpetic complications from shingles. Common types of neuralgia include trigeminal neuralgia, occipital neuralgia, and postherpetic neuralgia, each requiring tailored treatment approaches. Traditional pain relief methods such as nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids often provide limited relief, leading to increased demand for more effective treatments, including anticonvulsants, antidepressants, nerve blocks, and neuromodulation therapies. Advancements in neuralgia treatment now include minimally invasive surgical interventions such as microvascular decompression (MVD) and radiofrequency ablation (RFA), as well as emerging techniques like spinal cord stimulation (SCS) and targeted drug delivery systems. As the prevalence of chronic pain conditions rises globally, the neuralgia treatment market is witnessing increased investment in innovative pain management solutions that offer long-term relief and improved patient outcomes.

What Challenges Are Hindering Effective Neuralgia Treatment?

Despite advancements in pain management, several challenges continue to hinder the effective treatment of neuralgia. One of the primary concerns is the difficulty in accurately diagnosing neuralgia, as its symptoms can overlap with other neuropathic pain disorders, leading to misdiagnosis or delayed treatment. The complexity of nerve pain also means that treatment effectiveness varies significantly from patient to patient, requiring a trial-and-error approach that can prolong suffering. Additionally, many conventional neuralgia treatments, such as opioids, come with risks of dependency, addiction, and adverse side effects, necessitating the development of safer alternatives. High costs associated with advanced treatment options, including neuromodulation devices and surgical interventions, also limit accessibility, particularly in developing regions. Another major challenge is the lack of awareness and specialized pain management centers, leading to underdiagnosis and inadequate treatment for many patients. Furthermore, regulatory hurdles for novel pain management drugs and devices can delay market entry, restricting access to innovative neuralgia treatments. Addressing these challenges requires greater investment in research, enhanced medical training for healthcare providers, and improved access to affordable, evidence-based pain management therapies.

How Are Innovations Transforming Neuralgia Treatment?

The neuralgia treatment market is witnessing groundbreaking innovations aimed at improving pain relief, reducing side effects, and enhancing patient outcomes. One of the most promising advancements is the use of neuromodulation therapies, including transcutaneous electrical nerve stimulation (TENS), spinal cord stimulation (SCS), and dorsal root ganglion (DRG) stimulation, which modulate pain signals at the nerve level, providing long-term relief. Another major development is the emergence of targeted drug delivery systems that release pain medications directly at the affected nerve sites, reducing systemic side effects. Gene therapy and regenerative medicine are also gaining traction, with research exploring the potential of stem cell therapy and nerve growth factors to repair damaged nerves and restore normal function. Additionally, advancements in radiofrequency ablation (RFA) and cryoneurolysis are offering minimally invasive options for long-lasting pain relief by disrupting pain pathways without the need for extensive surgery. Artificial intelligence (AI) and machine learning are also being integrated into pain management, helping doctors personalize treatment plans based on patient-specific pain patterns and response data. As these innovations continue to evolve, the landscape of neuralgia treatment is shifting towards more effective, less invasive, and patient-centric solutions that offer lasting pain relief and improved quality of life.

What Is Driving the Growth of the Neuralgia Treatment Market?

The growth in the neuralgia treatment market is driven by several factors, including the rising prevalence of neuropathic pain disorders, increasing awareness of chronic pain management, and advancements in pain relief technologies. The aging global population, which is more prone to conditions such as shingles, diabetes-related nerve damage, and degenerative neurological diseases, is contributing to the rising incidence of neuralgia. Additionally, the growing emphasis on non-opioid pain management solutions is fueling the demand for alternative therapies, including neuromodulation, targeted drug delivery, and regenerative medicine. The expansion of pain management clinics and specialized healthcare facilities is also improving access to advanced neuralgia treatments, particularly in developed regions. Furthermore, increasing investments in research and development are accelerating the introduction of novel therapies, including biologics and AI-assisted treatment plans. Government initiatives promoting chronic pain management and reimbursement policies supporting innovative treatments are further boosting market growth. As neuralgia continues to be a significant public health concern, the demand for advanced, effective, and accessible treatment options is expected to rise, shaping the future of pain management and improving the lives of millions of affected individuals worldwide.

SCOPE OF STUDY:

The report analyzes the Neuralgia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Surgery-based Treatment, Drug-based Treatment); End-Use (Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Allergan plc
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc (GSK)
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Neuralgia Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Neuropathic Disorders Propels Demand for Neuralgia Treatment Solutions
    • Increasing Geriatric Population Base Strengthens Business Case for Long-Term Neuralgia Management
    • Growing Awareness Around Chronic Pain Conditions Drives Adoption of Early Intervention Therapies
    • Technological Advancements in Nerve Stimulation Devices Expand Addressable Market Opportunity
    • Emergence of Minimally Invasive Procedures Spurs Growth in Interventional Pain Management
    • Integration of AI and Predictive Analytics in Pain Diagnosis Enhances Precision and Supports Market Expansion
    • Increasing Availability of Targeted Drug Delivery Systems Drives Demand for Personalized Treatment
    • Shift Towards Multimodal Pain Therapy Approaches Drives Adoption of Complementary Treatments
    • Expansion of Telemedicine and Remote Care Solutions Accelerates Access to Neuralgia Treatment
    • Rising Investment in Pain Research and Innovation Pipelines Fuels Development of Next-Gen Therapeutics
    • Favorable Reimbursement Policies in Developed Economies Sustain Growth Momentum Across Key Markets
    • Escalating Use of Cannabinoid-Based Therapies Throws the Spotlight on Alternative Pain Management Modalities
    • Strong Pipeline of Biologics and Monoclonal Antibodies Expands Future Treatment Horizons
    • Increasing Regulatory Scrutiny on Opioid Usage Creates Opportunities for Safer Treatment Alternatives
    • Growing Collaboration Between Pharma and MedTech Players Spurs Innovation in Neurostimulation Technologies
    • Expansion of Pain Clinics and Specialty Care Centers Enhances Market Penetration in Emerging Regions
    • Rising Incidence of Diabetic Neuropathy and Post-Herpetic Neuralgia Drives Chronic Pain Treatment Demand
    • Increased Focus on Patient-Centric Care Models Strengthens Business Case for Home-Based Therapies
    • Regulatory Push for Non-Addictive Pain Therapies Drives Innovation in Drug Development Pipelines
    • Growth in Wearable and Implantable Pain Modulation Devices Drives Demand for Tech-Enabled Solutions
    • Adoption of Real-World Evidence (RWE) in Clinical Decision Making Enhances Market Credibility and Adoption
    • Government-Led Public Health Initiatives and Funding Support Expand Market Access in Underserved Regions
    • Surge in Mental Health Comorbidities with Chronic Pain Disorders Spurs Holistic Treatment Approaches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neuralgia Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Neuralgia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Neuralgia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Neuralgia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Surgery-based Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Surgery-based Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Surgery-based Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Drug-based Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Drug-based Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Drug-based Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospital & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Neuralgia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Neuralgia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Neuralgia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Neuralgia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Neuralgia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Neuralgia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Neuralgia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Neuralgia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Neuralgia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Neuralgia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Neuralgia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Neuralgia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Neuralgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Neuralgia Treatment by Treatment Type - Surgery-based Treatment and Drug-based Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Neuralgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery-based Treatment and Drug-based Treatment for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Neuralgia Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Neuralgia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION